The 36-month beta value for BEAM is at 1.87. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BEAM is 76.90M, and currently, shorts hold a 15.34% of that float. The average trading volume for BEAM on July 23, 2024 was 1.31M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BEAM) stock’s latest price update
Beam Therapeutics Inc (NASDAQ: BEAM)’s stock price has plunge by 10.20relation to previous closing price of 27.05. Nevertheless, the company has seen a 9.23% surge in its stock price over the last five trading sessions. investorplace.com reported 2024-07-22 that Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options.
BEAM’s Market Performance
Beam Therapeutics Inc (BEAM) has seen a 9.23% rise in stock performance for the week, with a 29.95% gain in the past month and a 23.69% surge in the past quarter. The volatility ratio for the week is 6.09%, and the volatility levels for the past 30 days are at 5.33% for BEAM. The simple moving average for the past 20 days is 20.15% for BEAM’s stock, with a 11.57% simple moving average for the past 200 days.
Analysts’ Opinion of BEAM
JP Morgan, on the other hand, stated in their research note that they expect to see BEAM reach a price target of $40, previously predicting the price at $38. The rating they have provided for BEAM stocks is “Overweight” according to the report published on January 29th, 2024.
BofA Securities gave a rating of “Neutral” to BEAM, setting the target price at $35 in the report published on December 15th of the previous year.
BEAM Trading at 22.36% from the 50-Day Moving Average
After a stumble in the market that brought BEAM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.78% of loss for the given period.
Volatility was left at 5.33%, however, over the last 30 days, the volatility rate increased by 6.09%, as shares surge +17.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +29.50% upper at present.
During the last 5 trading sessions, BEAM rose by +6.96%, which changed the moving average for the period of 200-days by +35.52% in comparison to the 20-day moving average, which settled at $25.03. In addition, Beam Therapeutics Inc saw 9.52% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BEAM starting from Simon Amy, who sale 748 shares at the price of $22.95 back on Jul 02 ’24. After this action, Simon Amy now owns 68,805 shares of Beam Therapeutics Inc, valued at $17,167 using the latest closing price.
Simon Amy, the Chief Medical Officer of Beam Therapeutics Inc, sale 502 shares at $23.76 during a trade that took place back on Jul 01 ’24, which means that Simon Amy is holding 69,553 shares at $11,928 based on the most recent closing price.
Stock Fundamentals for BEAM
Current profitability levels for the company are sitting at:
- -0.5 for the present operating margin
- 0.93 for the gross margin
The net margin for Beam Therapeutics Inc stands at -0.37. The total capital return value is set at -0.15. Equity return is now at value -16.09, with -10.01 for asset returns.
Based on Beam Therapeutics Inc (BEAM), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -0.83. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -7.37.
Currently, EBITDA for the company is -156.47 million with net debt to EBITDA at 0.67. When we switch over and look at the enterprise to sales, we see a ratio of 6.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.99.
Conclusion
In conclusion, Beam Therapeutics Inc (BEAM) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
